Announcements
- Document d'enregistrement Universel 2023
- Availability of Transgene's 2023 Universal Registration Document
- MIse à disposition du document d'enregistrement universel 2023 de Transgene
- Transgene et NEC présentent les premiers signes de bénéfice clinique de leur vaccin individualisé contre le cancer, TG4050, dans les cancers de la tête et du cou à l’AACR 2024
- Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
- Transgene nomme Lucie Larguier en tant que Directrice Financière et Christelle Schwoerer Comme Directrice des Ressources Humaines
- Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
- Transgene prévoit des avancées significatives sur son portefeuille d’immunothérapies en 2024 et étend sa visibilité financière jusqu’au 4ème trimestre 2025
- Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
- Transgene Announces Upcoming Investor Meetings
More ▼
Key statistics
On Friday, Transgene SA (TGNA:MUN) closed at 1.45, 36.72% above the 52 week low of 1.06 set on Mar 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.45 |
---|---|
High | 1.45 |
Low | 1.45 |
Bid | -- |
Offer | -- |
Previous close | 1.45 |
Average volume | 797.00 |
---|---|
Shares outstanding | 100.85m |
Free float | 35.05m |
P/E (TTM) | -- |
Market cap | 139.38m EUR |
EPS (TTM) | -0.2227 EUR |
Data delayed at least 15 minutes, as of Apr 19 2024 07:14 BST.
More ▼